2025 Approvals
GOMEKLI(mirdametinib): A New Treatment for Neurofibromatosis Type 1 Approved by the FDA on February 11 2025
What is it prescribed for? GOMEKLI is prescribed for adults and children 2 years and older with neurofibromatosis type 1 (NF1) who have symptomatic plexiform neurofibromas (PN) that cannot be completely removed by surgery . What is the name of the drug and what does it do? The brand name is